Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients

Kidney International

Volumn 67, Issue 6, 2005, Pages 2361-2367

  Kutsogiannis, Demetrios J ^a   Gibney, R T Noel ^a   Stollery, Daniel ^a   Gao, Jun ^a  

^a ROYAL ALEXANDRA HOSPITAL   (Canada)

Author keywords

Anticoagulation; Antithrombin III; Continuous renal replacement therapy; Trisodium citrate

Indexed keywords

ANTITHROMBIN III; CITRIC ACID; HEPARIN; ANTICOAGULANT AGENT; CITRATE SODIUM;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYPOCALCEMIA; MALE; METABOLIC ALKALOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT OUTCOME; COMPARATIVE STUDY; GENETIC LINKAGE; METHODOLOGY; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADULT; AGED; ANTICOAGULANTS; ANTITHROMBIN III; CITRATES; CRITICAL ILLNESS; FEMALE; HEPARIN; HUMANS; KIDNEY FAILURE, ACUTE; LOD SCORE; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 23044466767     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00342.x     Document Type: Article

References (39)

1. MARTIN GS, MANNINO DM, EATON S, MOSS M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554, 2003
2. LIANO F, PASCUAL J: Outcomes in acute renal failure. Semin Nephrol 18:541-550, 1998
3. MCCARTHY JT: Prognosis of patients with acute renal failure in the intensive-care unit: A tale of two eras. Mayo Clin Proc 71:117-126, 1996
4. BRIVET FG, KLEINKNECHT DJ, LOIRAT P, LANDAIS PJ: Acute renal failure in intensive care units-Causes, outcome, and prognostic factors of hospital mortality: A prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med 24:192-198, 1996
5. LIANO F, PASCUAL J: Epidemiology of acute renal failure: A prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. Kidney Int 50:811-818, 1996
6. MANNS M, SIGLER MH, TEEHAN BP: Continuous renal replacement therapies: An update. Am J Kidney Dis 32:185-207, 1998
7. KELLUM JA, MEHTA RL, ANGUS DC, et al: The first international consensus conference on continuous renal replacement therapy. Kidney Int 62:1855-1863, 2002
8. MEHTA RL, LETTERI JM: Current status of renal replacement therapy for acute renal failure. A survey of US nephrologists. The National Kidney Foundation Council on Dialysis. Am J Nephrol 19:377-382, 1999
9. HYMAN A, MENDELSSOHN DC: Current Canadian approaches to dialysis for acute renal failure in the ICU. Am J Nephrol 22:29-34, 2002
10. PALSSON R, NILES JL: Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 55:1991-1997, 1999
11. KUTSOGIANNIS DJ, MAYERS I, CHIN WD, GIBNEY RT: Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis 35:802-811, 2000
12. MONCHI M, BERGHMANS D, LEDOUX D, et al: Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 30:260-265, 2004
13. LAVAUD S, CANIVET E, WUILLAI A, et al: Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane. Nephrol Dial Transplant 18:2097-2104, 2003
14. LE GALL JR, KLAR J, LEMESHOW S, et al: The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. JAMA 276:802-810, 1996
15. HEBERT PC, WELLS G, BLAJCHMAN MA, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340:409-417, 1999
16. KAPLAN EL, MEIER P: Nonparametric estimation from incomplete observations. JASA 53:457-481, 1958
17. THERNEAU TM, GRAMBSCH PM: Modeling Survival Data. Extending the Cox Model, 1st ed., New York, Springer-Verlag, 2000, p 350
18. DIGGLE PJ, LIANG K, ZEGER SL: Analysis of Longitudinal Data, New York, Oxford, 1994, p 253
19. LACHIN JM: Biostatistical Methods. The Assessment of Relative Risks, 1st ed., New York, John Wiley & Sons, 2000
20. LACHIN JM, FOULKES MA: Evaluation of sample size and power for analysis of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42:507-519, 1986
21. O'BRIEN PC, FLEMING TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
22. RONCO C, BELLOMO R, HOMEL P, et al: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356:26-30, 2000
23. SCHEINKESTEL CD, KAR L, MARSHALL K, et al: Prospective randomized trial to assess caloric and protein needs of critically ill, anuric, ventilated patients requiring continuous renal replacement therapy. Nutrition 19:909-916, 2003
24. SEHGAL AR: Improving hemodialysis patient outcomes: A step-by-step approach. Semin Dial 15:35-37, 2002
25. UCHINO S, FEALY N, BALDWIN I, et al: Continuous is not continuous: The incidence and impact of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration. Intensive Care Med 29:575-578, 2003
26. SCHIFFL H, LANG SM, FISCHER R: Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 346:305-310, 2002
27. HOFBAUER R, MOSER D, FRASS M, et al: Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int 56:1578-583, 1999
28. GABUTTI L, MARONE C, COLUCCI G, et al: Citrate anticoagulation in continuous venovenous hemodiafiltration: A metabolic challenge. Intensive Care Med 28:1419-1425, 2002
29. BALDWIN I, TAN HK, BRIDGE N, BELLOMO R: Possible strategies to prolong circuit life during hemofiltration: Three controlled studies. Ren Fail 24:839-848, 2002
30. UCHINO S, FEALY N, BALDWIN I, et al: Continuous venovenous hemofiltration without anticoagulation. ASAIO J 50:76-80, 2004
31. REEVES JH, CUMMING AR, GALLAGHER L, et al: A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 27:2224-2228, 1999
32. VARGAS HEIN O, VON HEYMANN C, LIPPS M, et al: Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med 27:673-679, 2001
33. CUTTS MW, THOMAS AN, KISHEN R: Transfusion requirements during continuous veno-venous haemofiltration-The importance of filter life. Intensive Care Med 26:1694-1697, 2000
34. SHULMAN RI, SINGER M, ROCK J: Continuous renal replacement therapy. Keeping the circuit open: Lessons from the lab. Blood Purif 20:275-281, 2002
35. OTA K, AKIZAWA T, HIRASAWA Y, et al: Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol Dial Transplant 18:1623-1630, 2003
36. ROEMISCH J, GRAY E, HOFFMANN JN, WIEDERMANN CJ: Antithrombin: A new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 13:657-670, 2002
37. WHITE B, PERRY D: Acquired antithrombin deficiency in sepsis. Br J Haematol 112:26-31, 2001
38. OPAL SM: Therapeutic rationale for antithrombin III in sepsis. Crit Care Med 28:S34-S37, 2000
39. WARREN BL, EID A, SINGER P, et al: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 286:1869-1878, 2001